Member Info for BuenaVista

If the drug is novel and hasn't previously been disclosed, then yes, each can be patented.

I'd like it to be later than within the next fortnight, solely because I'd like the FDA to consider the early data from C7 when setting the initial dose for the fortnightly dosing trial.

Assuming, of course, MTD isn't found in C7, an initial dose of 256mg/m² would be very, very good news as that is two thirds of 385 (so the same total dosing over six weeks) and if MTD is not found the 25% increase steps are to 320 and 400, this last one being equivalent to 600mg/m² of AVA6000 given 3-weekly and 5.4 times the standard 75mg/m² dose of doxorubicin. It is also 6.75 times the standard 60mg/m² dose of doxorubicin...

Of course, MTD would still need to elude the trial for this to come about but if we did make it to 400mg/m² of AVA6000 fortnightly then that would surely blow the doors off?!

In any case, the higher the initial fortnightly dose, the more impressed the FDA will have been with the data and the quicker we can move up in 25% increases.

It wouldn't surprise me if we get news of the parallel study in the US being approved AND the Phase 1a data release within days of each other or even in the same announcement.

Inhonour of 🐑 in his 🩳

😂😂😂 🤡

Avacta wouldn't waste their time bothering about those scum. Whatever they say and do doesn't affect the company's prospects, only the wealth of people who buy Avacta shares without being adequately researched.

Uh-oh! Trader-mode alert. I suggest you examine the company Moneysponge, as you did for Avacta, and you might realise that this is actually a company with prospects in a sector with prospects.

Forget the UK market for the time being. For as long as the country is run by those Tory clowns it will only go backwards. AFC has identified Europe and MENA as where the future lies: https://www.lse.co.uk/rns/AFC/stade-update-cnjzaqa2yfztzky.html and https://www.lse.co.uk/rns/AFC/exclusive-distribution-agreement-with-tamgo-y51gvrdhpowyf1w.html

The true nature of the rat that is Ade and the completely made up toxic lies that it posts:

Ade1234 Premium Member

Posted in: WOSG

Today 21:15

RE: Just Reading

Money, thanks for private messaging me to apologise and now you have told me your situation, I’m sorry also.

Being in lots of debt and living on your sisters sofa doesn’t sound like much fun, I’m sure you will be ok and there is loads of jobs around ATM so you should hopefully get off the Dole soon to.

All the best mate, I appreciate you reaching out and I hope your infection gets better soon also.

https://www.lse.co.uk/profiles/ade1234/

Big losses incoming for the ignorant and gullible. 😂😂😂

Maybe stop subscribing to TW's rag in future? 🤣🤣🤣

"Although some drugs have shown good efficacy in individual subtypes, none have exceeded the efficacy and safety achieved by doxorubicin for STSs."

Hence Dr Tap's comment about the possibility of AVA6000 becoming the standard of care overnight. 👍

Maybe Avacta are thinking of reversing into a NASDAQ-listed company as a shortcut? Autolus, a CAR T-cell oncology company across the road at Scale Space but with a US presence and GMP manufacturing in Stevenage comes to mind. And yes, I'm invested in that company as well - ongoing pivotal study in haematological cancers and due to submit BLA by year end ( https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-announces-pivotal-phase-2-felix-clinical ). I did wonder why CAR-T was a subject at Science Day.

EF has a great realxed personality and self-deprecating sense of humour. Very pleased to have him onboard. I should think he's a very effective negotiator.

In the realm of criticism, they converge, - Ade, Daz, and Garonne, their voices urge, - To cast their shadows on AFC's design, - Yet, beneath their words, a secret they entwine.

Ade, the skeptic with a discerning eye, - Daz, the cynic, always questioning why, - Garonne, a name, but a phantom in the mix, - Together they contrive, their clever trick.

Are Ade and Daz the puppeteers behind the screens? - Their criticisms cunning, synchronized routines? - With Garonne as the veil, a smokescreen to deploy, - To bash AFC's efforts, with a cryptic ploy.

Or could it be Ade and Garonne in disguise? - With Daz as the mask, concealing their ties, - Their criticism a façade, a well-played charade, - In this complex dance, where untruths are laid.

Perhaps Daz and Garonne, with Ade as the ruse? - Their critiques strategically meant to confuse, - In this intricate puzzle, the answer's unclear. - Which two among them are truly here?

In this tale of shadows, where façades abound, - The truth may linger, deep underground, - Ade, Daz, and Garonne, a mysterious crew, - In the realm of AFC, their lies they construe.

"Why don't you play the ball instead of the man Buena? Tell us why you thing Daz's figures are wrong, if you can."

I'm sure there's a name for this sort of fallacious argument:

"Daz's mum spent £36.29 in Tesco yesterday. Now prove me wrong."

"There is a china teapot revolving about the sun in an elliptical orbit between the Earth and Mars. Prove that wrong."

You see how it goes?

Garonne is an astoundingly stupid person. Prove me wrong.

Don't "think it was £4m this year and £11m next year" Daz, research it and cite your source along with your assertion.

For the prevention of any belief in any of what Daz wrote, he pulled those figures out of his backside.

NEVER believe anything a basher like Daz says unless it is qualified by a citation to a reputable source.

Caveat lector... https://www.lse.co.uk/profiles/daz9643/

Daz, your posts mean absolutely nothing as anyone giving your posting history a cursory scan can immediately tell that you are 100% an AFC-dedicated basher. Your reason for being here day after day, week after week, month after month, year after year? Money or madness. You're certainly not to be trusted to tell the truth.

https://www.lse.co.uk/profiles/daz9643/

I've gotta say a research code such as AVA028 normally refers to a single compound.

Also, that other companies start at 101 (102, 103, etc) for compounds active against one target or in one class and 201 (202, 203, etc) for the next one. It seems odd that Avacta use seemingly random research codes and group several compounds together under one research code - something that makes it look as though they don't have much in the cupboard.

It is part of AVA028. They should draw it out separately soon and progress it rightwards into preclinical.

"AVA028 – PD-L1 Affimer® / ImmunoCytokines

"The flexibility of Affimer technology allows multiple formatting configurations to generate multispecific molecules. These molecules utilise the tumour cell homing functionality of the PD-L1 inhibitory Affimer to bring immunomodulatory cytokines directly to the tumour and reverse the immunosuppressive tumour microenvironment by enhancing T cell activation but avoiding T cell exhaustion. A number of potential ImmunoCytokines are under development."

https://avacta.com/therapeutics/pipeline/

@JT, yes I saw that but took it too mean that biweekly dosing as first line treatment for STS was the aim for regristration. However, reading it more closely it could mean trialing in Phase 1a as a first line treatment. However, the RNS also says "intends", so nothing is certain until the FDA approves it, which is why Alan only talked about dose escalation for that study and not about anthracycline naive patients.

JT, I hadn't twigged. Where is it stated (printed or said) that the patients in Phase 1aMk2 will be anthracycline naive?

Here you are: https://patents.google.com/patent/US10844370B2/en

Enjoy